The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immunotherapy for biochemically recurrent prostate cancer.
 
Ravi Amrit Madan
Speakers' Bureau - Boehringer Ingelheim (I); Janssen (I); Pfizer (I)
 
Fatima Karzai
No Relationships to Disclose
 
Marijo Bilusic
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon
Speakers' Bureau - Dendreon
Research Funding - Ambry Genetics (Inst); Bavarian Nordic (Inst); Johnson & Johnson (Inst); Sotio (Inst)
 
Julius Strauss
No Relationships to Disclose
 
Susan F. Slovin
Consulting or Advisory Role - Bayer
 
Lauren Christine Harshman
Consulting or Advisory Role - Corvus Pharmaceuticals; Dendreon; Genentech; KEW; Medivation/Astellas; Merck; NCCN; Pfizer; PlatformQ Health; Theragene
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology; Medivation/Astellas (Inst); Merck (Inst); Sotio (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Sanofi
 
Marc Robert Theoret
No Relationships to Disclose
 
Philip M. Arlen
Employment - Precision Biologics
Leadership - Precision Biologics
Stock and Other Ownership Interests - Precision Biologics
 
Myrna Rauckhorst
No Relationships to Disclose
 
Anna Couvillon
No Relationships to Disclose
 
Amy Hankin
No Relationships to Disclose
 
Monique Williams
No Relationships to Disclose
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; Druggablity Technologies; Placon; Tarveda Therapeutics
Consulting or Advisory Role - Astellas Pharma; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; BIND Biosciences; Druggablity Technologies; Genentech/Roche; GTx; Ipsen; Janssen; Merck; Metamark Genetics; MorphoSys; MTG Therapeutics; Omnitura; OncoCellMDX; Oncogenex; Progenity; Sanofi; Tarveda Therapeutics; Thermo Fisher Scientific
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Bayer (Inst); Dendreon (Inst); Exelixis (Inst); Janssen (Inst); Medivation (Inst); Oncogenex (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Composition and Methods for Screening and Diagnosis of Prostate Cancer; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods and Kits for Determining Sensitivity to Cancer Treatment; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent); Up-to-Date Royalties; Wolters Kluwer Royalties
Expert Testimony - Janssen; Sanofi
Travel, Accommodations, Expenses - Sanofi; Tarveda Therapeutics
 
William L. Dahut
No Relationships to Disclose
 
Jeffrey Schlom
Research Funding - Bavarian Nordic (Inst)
Patents, Royalties, Other Intellectual Property - If applicable; If applicable (Inst)
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Celgene (Inst); EMD Serono (Inst); Pfizer (Inst)